Latest Research Collaboration News

Page 1 of 9
WhiteHawk reported a US$313,000 operating cash outflow for the September quarter, while a new A$1.5 million debt facility and A$1.24 million in annualised cost savings support its next phase. The post-quarter completion of Quixxi adds AI governance products, international customers and a four-year A$635,238 Italian contract, but revenue conversion remains the test.
Victor Sage
Victor Sage
30 Oct 2026
GWR Group returned $19.85 million to shareholders during the September quarter, but its balance sheet remains exposed to unresolved Wiluna West liabilities. The company says $12.69 million in State royalties is overdue while the transfer of the tenements to Gold Valley remains incomplete.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
HITIQ has expanded its military research ambitions and added fresh funding during the September quarter, but the company ended the period with $658,242 in cash and estimated funding for only one quarter. Its US collaboration remains non-binding, leaving financing and commercial execution as the immediate tests.
Victor Sage
Victor Sage
30 Oct 2026
Basin Energy’s Newmans rare earth discovery has expanded from 3.3 km to 6.7 km, with drilling producing the project’s strongest magnet rare earth results to date. The technical momentum comes with a sharper funding question, as cash stood at A$776,000 and covered an estimated 1.53 quarters of current outgoings.
Victor Sage
Victor Sage
30 Oct 2026
Battery Age Minerals advanced its Bleiberg germanium permits and expanded Falcon Lake to about 60 km², but its cash position now covers an estimated 1.34 quarters of funding. Initial Apex fieldwork also failed to confirm the remote-sensing anomalies that had defined the Utah targets.
Victor Sage
Victor Sage
30 Oct 2026
Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.
Ada Torres
Ada Torres
26 Oct 2026
Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.
Ada Torres
Ada Torres
20 Oct 2026
First Graphene has signed a three-year agreement with Turkish manufacturer Aeropreg to develop and potentially commercialise PureGRAPH-enhanced carbon fibre prepreg. The partnership offers a clearer route into aerospace, defence and automotive supply chains, but commercial launch remains dependent on trial results.
Victor Sage
Victor Sage
5 Oct 2026
Locksley Resources has halted active field exploration across its Mojave antimony and rare earths project after antimony prices fell more than 57% from mid-2025 peaks. The strategic reset came as the company reported a widened FY26 loss of A$15.65 million and shifted attention to copper-gold assets in New South Wales.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Pure Resources finished 2026 with $3.67 million in cash and no debt after raising $4.7 million, but its annual loss widened as it shifted from explorer to a Garnet Hills-led advanced materials platform. The company is now pursuing garnet abrasives, jumbo flake graphite and heavy rare earth recovery through US research and defence partnerships.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Basin Energy has secured a three-year research collaboration with James Cook University to investigate improved extraction and recovery of heavy rare earths at its Sybella-Barkly project. The deal carries no cash payment, but JCU will own the resulting project intellectual property and data.
Victor Sage
Victor Sage
16 Sept 2026

Browse the archive

Full archive